| Literature DB >> 29264461 |
Gaurang Deshpande1, Rudo F Mapanga1, M Faadiel Essop1.
Abstract
The incidence of noncommunicable diseases is on the rise and poses a major threat to global public health. This is in parallel to a steady increase in worldwide intake of sugar-sweetened beverages (SSBs) among all age groups. As several studies demonstrated a controversial relationship between SSB consumption and the metabolic syndrome (MetS), this mini-review focuses on links between its intake and (1) MetS, (2) prediabetes/type 2 diabetes mellitus (T2DM), and (3) hypertension. A detailed search for clinical and observational studies published during the past 10 years was conducted using key terms that link SSBs to the MetS, T2DM, and hypertension. Here we excluded all meta-analyses and also literature that solely focused on obesity. The analysis revealed that most epidemiological studies strongly show that frequent SSB intake contributes to the onset of the MetS in the longer term. Some of the findings also show that regular SSB intake can alter glucose handling and insulin sensitivity, thereby contributing to the development of the MetS and T2DM. There is also evidence that frequent SSB intake (and particularly fructose) is linked to hypertension and well-known cardiovascular disease risk factors. However, some studies report on the lack of negative effects as a result of SSB consumption. Because of this discrepancy, we propose that well-designed long-term clinical studies should further enhance our understanding regarding the links between SSB consumption and the onset of cardiometabolic diseases.Entities:
Keywords: cardiometabolic risk; hypertension; metabolic syndrome; sugar-sweetened beverages; type 2 diabetes mellitus
Year: 2017 PMID: 29264461 PMCID: PMC5686631 DOI: 10.1210/js.2017-00262
Source DB: PubMed Journal: J Endocr Soc ISSN: 2472-1972
SSB Consumption and Risk of MetS
| Author | Cohort/Location | Participants | Average Follow-up Period | Range of SSB Intake/d | Elevated Risk Factors of MetS | Confounder Adjustment | |||
|---|---|---|---|---|---|---|---|---|---|
| N | Age (Mean/Range), y | Sex | |||||||
| Barrio-Lopez | SUN Project; Spain | 8157 | 36 | M and F | 6 y | 0–2.4 servings | BP; WC; TAG | BP ( | Yes |
| Khosravi-Boroujeni | Iran | 1752 | 39.4 ± 14.2 (F); 41.6 ± 16.7 (M) | M and F | Cross-sectional study | <1/wk to >3/wk | DBP in females | Yes | |
| Chan | Taiwan | 2727 | 12–16 | M and F | Cross-sectional study | 0/d; 1–500 mL/d and >500 mL/d | WC; TGs; SBP in males | Metabolic risk cluster ( | Yes |
| Wang | QUALITY study, Canada | 633 | 8–10 | M and F | 8 y | Median SSB intake 146 mL/d | HOMA-IR; SBP; WC | In overweight children, HOMA-IR (increase) ( | Yes |
| Hernandez-Cordero | Mexico | 240 | 18–45 | F | 9 mo | 418 ± 11 mL/d | No elevated risk factors observed | NA | No |
| Mattei | Costa Rica | 1872 | 49–70.3 | M and F | Cross-sectional study | None to ≥1 serving /d | WC; TGs; higher odds of MetS | WC ( | Yes |
| Denova-Gutierrez | Mexico | 8307 | 20–70 | M and F | Cross-sectional study | None to >2 servings/d | Prevalence of MetS higher in obese subjects; increased TGs; reduced HDL | 26.65 obese people had MetS; 0.49-mmol/L increase in TGs/additional SSB consumption; 0.39-mmol/l decrease in HDL/additional SSB consumption | Yes |
| Loh | Malaysia | 873 | 13 | M and F | Cross-sectional study | 110–190 mL/d | Elevated TGs; FBG; insulin; insulin resistance; low HDL-C | None were statistically significant | Yes |
| Dhingra | Framingham Offspring study; United States | 6039 | 46–66 | M and F | Cross-sectional study | <1 to ≥2 servings/d | Increased prevalence of MetS; obesity; WC; fasting glucose; blood pressure; TGs; HDL | Increased MetS (OR, 1.48; 95% CI, 1.30–1.69); Obesity (OR, 1.31; 95% CI, 1.02–1.68); WC (OR, 1.30; 95% CI, 1.09–1.56); fasting glucose (OR, 1.25; 95% CI, 1.05–1.48); BP (OR, 1.18; 95% CI, 0.96–1.44); TGs (OR, 1.25; 95% CI, 1.04–1.51); HDL (OR, 1.32; 95% CI, 1.06–1.64) | Yes |
| Duffey | CARDIA study; United States | 2774 | 25 ± 3.6 (at start) | M and F | 20 y | Average intake over 7 y | WC; TG; LDL; hypertension | WC ( | Yes |
| Ambrosini | Raine study; Australia | 1433 | 14 (at start) | M and F | 14 y | None to >1.3 servings/d | BMI; obesity risk; TGs; HDL | Girls consuming >1.3 servings/d had increased BMI and obesity risk ( | |
| Ferreira- Pêgo | PREDIMED; Spain | 1868 | M: 55–80 F: 60–80 (at start) | M and F | <1 to >5/wk | Yes | |||
| Kang and Kim ( | KoGES | 5797 | 40–69 | 10 y | <1 to >5/wk | BMI; fasting glucose; blood pressure; TGs; HDL | Females consuming >4 servings/wk showed increased BMI ( | Yes | |
Abbreviations: BP, blood pressure; CARDIA, coronary artery risk development in young adults; CI, confidence interval; DBP, diastolic blood pressure; F, female; FBG, fasting blood glucose; HDL, high-density lipoprotein; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, HOMA-IR, homeostatic model assessment–insulin resistance; KoGES, Korean Genome and Epidemiology Study; LDL, low-density lipoprotein; M, male; NA, not applicable; OR, odds ratio; QUALITY, Quebec Adipose and Lifestyle Investigation in Youth; SBP, systolic blood pressure; SUN, Seguimiento Universidad de Navarra; TAG, triacylglycerol; TG, triglyceride; WC, waist circumference.
SSB Consumption and Risk of T2DM
| Author | Cohort/Location | Participants | Average Follow-up Period | Mean SSB Intake/d | Risk of T2DM | Confounder Adjustment | |||
|---|---|---|---|---|---|---|---|---|---|
| N | Age (Mean/Range), y | Sex | |||||||
| De Koning | HPFS; United States | 40,389 (2680 developed diabetes) | 40–75 | M and F | 20 y | 887 mL/d | HR, 1.25 (95% CI, 1.11–1.39) vs nonconsumers | <0.01 | Yes |
| Fagherazzi | E3N study; France | 66,118 | 52.6 ± 6.6 | F | 14 y | 328.3 mL/d | HR, 1.34 (95% CI, 1.05–1.71) vs nonconsumers | 0.0002 | Yes |
| The InterAct Consortium ( | EPIC database; 8 European countries | 11,684 | 41–62 | M and F | 16 y | <1 glass/mo to ≥1 glass/d | HR, 1.22 (95% CI, 1.09–1.38) increase with one serving of SSB | 0.86 | Yes |
| Lofvenborg | ESTRID study; Sweden | 2864 | 45.2–71.8 | M and F | 5 y | None to >2 servings/d | OR increased to 2.39 (95% CI, 1.39–4.09); 20% increase with each additional serving | Not available | Yes |
| Maki | 43 (n = 21 for SSB) | 53.8 ± 2.1 | M and F | 14 wk | 2160 ± 91.7 kcal/d | SSB consumption is associated with less favorable values for T2DM risk | Not available | Yes | |
| Palmer | Black Women’s Health Study, United States | 43,960 | 29–49 | F | 10 y | <1 to ≥2/d | Incident rate ratio was 1.51 (95% CI, 1.31–1.75) vs fruit juice | 0.002 | Yes |
| Sakurai | Japan | 2037 | 35–55 | M | 7 y | 0 to ≥1 serving/d | HR, 1.34 (0.72– 2.36), ≥ 1 serving/d vs rare/never | 0.424 | Yes |
| Teshima | Mihama Diabetes Prevention Study; Japan | 93 | 40–69 | M and F | 3.6 ± 0.2 y | No intake to daily intake | OR, 3.26 (95% CI, 1.17–9.06) vs no SSB intake | 0.001 | No |
| Odegaard | Singapore | 43,580 | 45–74 | M and F | 5.7 y | None to 2–3 servings/wk | RR, 1.42 (95% CI, 1.25–1.62) vs no SSB intake | Yes | |
Abbreviations: CI, confidence interval; ESTRID, Epidemiological Study of Risk Factors for LADA and Type 2 Diabetes; E3N, Etude Epidémiologique auprès des femmes de la Mutuelle Générale de l’Education Nationale; F, female; HPFS, Health Professionals Follow-up Study; HR, hazard ratio; M, male; OR, odds ratio; RR, relative risk.
SSB Consumption and Risk of Hypertension
| Author | Cohort/Location | Participants | Average Follow-up Period | Maximum SSB Intake | Mean Systolic Pressure (mm Hg) After High SSB Intake | Mean Diastolic Pressure (mm Hg) After High SSB Intake | Confounder Adjustment | |||
|---|---|---|---|---|---|---|---|---|---|---|
| N | Age (Mean/Range), y | Sex | ||||||||
| Brown | INTERMAP; United States, United Kingdom | 2696 | 48.8–50.8 | M and F | 3 y | 306 mL/d (United States) | 122.5 mm Hg | 75.5 mm Hg | <0.001 | Yes |
| 66 mL/d (United Kingdom) | ||||||||||
| Chen | PREMIER; United States | 810 | 25–79 | M and F | 18 mo | 310.5 ± 351.9 mL/d | 133.2 mm Hg | 85.0 mm Hg | 0.57 (SBP); 0.01 (DBP) | Yes |
| Cohen | NHS I, NHS II and HPFS; United States | 223,891 | 39–52 (NHS I); 31–40 (NHS II); 42–63 (HPFS) | F (NHS I); F (NHS II); M and F (HPFS) | 38 y (NHS I); 16 y (NHS II); 22 y (HPFS) | 354.8 mL/d | >140 mm Hg (HPFS) | >90 mm Hg (HPFS); HR, 1.13 (95% CI, 1.09–1.17) ≥1 serving/d vs <1/mo | Not stated | Yes |
| Green | Cohort used from Framingham; United States | 5107 | 40.8–53.9 (combined) | M and F | 354.8 mL/d (7 servings/wk) | 54.6% increase in SBP vs normal weight | 59.7% increase in DBP vs normal weight | <0.001 | Yes | |
| Sayon-Orea | SUN; Spain | 1308/13,843 | 36.4 | M and F | 8.1 y | ≥354.8 mL/d (≥ 7 servings/wk) | HR, 1.33 (95% CI, 1.08–1.68) vs no SSB consumption | 0.007 | Yes | |
| Souza | Brazil | 559 | 9–16 | M and F | Once off study | +709.6 mL/d (+2 servings/d) | 102.6 mm Hg | 58.8 mm Hg | 0.01 (SBP); 0.04 (DBP) | Yes |
| Kim | NHANES; South Korea | 3044 | ≥19 | M and F | Cross-sectional study | None to 6 times/d | SSBs 3 times/d associated with 1.74 times higher prevalence of hypertension (95% CI, 1.00–3.01) | 0.05 | Yes | |
| Nguyen | NHANES; United States | 4867 | 12–18 | M and F | Cross-sectional study | 0 to >36 oz/d | Data not shown | Data not shown | 0.03 (SBP); 0.09 (DBP) | Yes |
Abbreviations: CI, confidence interval; DBP, diastolic blood pressure; F, female; HPFS, Health Professionals Follow-up Study; HR, hazard ratio; M, male; NHANES, National Health and Nutritional Examination Survey; NHS, Nurses’ Health Study; PREMIER, a randomized trial to determine the effects of multi-component lifestyle interventions on blood pressure; SBP, systolic blood pressure.